Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

The $18-per-share offer represents a 25% premium over AMAG's stock price as of Aug. 2, but it's not enough to return the anemia drug maker's valuation to the days just before it unveiled the Allos deal on July 20.
Advertisement

Related Content

Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Investors Balk At AMAG-Allos Proposed Marriage
Investors Balk At AMAG-Allos Proposed Marriage
Chronic Kidney Disease Drug Developers Jockey For Position In Era Of Change
AMAG Pharmaceuticals: Enough Irons In The Fire?

Topics

Advertisement
UsernamePublicRestriction

Register

PS072706

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel